Ronald Levy, MD
Publication Details
-
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
J Clin Oncol. 2010; (28): 4324-32
Combining tumor antigens with an immunostimulant can induce the immune system to specifically eliminate cancer cells. Generally, this combination is accomplished in an ex vivo, customized manner. In a preclinical lymphoma model, intratumoral injection of a Toll-like receptor 9 (TLR9) agonist induced systemic antitumor immunity and cured large, disseminated tumors.
Help